Figures
- Figure 1.
Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected (- - - -) and observed (––––) survival rates and b) age-/sex-matched survival rates. Reproduced from [13] with permission from the publisher.
Tables
- Table 1. Demographics of idiopathic pulmonary arterial hypertension patients over time
Registry [Ref.] Time period Age years Female 1-year survival US NIH registry [17, 20] 1981–1988 36±15 63 68 French registry# [4, 19, 23] 2002–2003 52±15 62 89 US REVEAL [3, 9, 12] 2006–2009 50±15 80 88 PH registry of the UK and Ireland#,¶ [6] 2001–2009 50±17 70 93 COMPERA+ [13] 2007–2011 65±15 60 92 New Chinese registry [26] 2008–2011 38±13 70 92 Czech registry [7] 2000–2007 52±17 65 89¶ Data are presented as mean±sd or %, unless otherwise stated. NIH: National Institutes of Health; REVEAL: Registry to Evaluate Early and Long-term PAH Disease Management; PH: pulmonary hypertension; COMPERA: Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension. #: included idiopathic pulmonary arterial hypertension (PAH), familial/heritable PAH and anorexigen-associated PAH; ¶: incident population; +: countries involved included Austria, Belgium, Germany, Italy, the Netherlands, Switzerland and the UK.
- Table 2. Relationship between reduced diffusing capacity of the lung for carbon monoxide (DLCO) and patient/disease characteristics
Trip [41] Chandra [44] DLCO <45% DLCO ≥45% p-value DLCO <43% DLCO 43–64% DLCO >64% p-value Subjects n 48 118 135 135 138 Age years 67# 46# <0.001 55¶ 47¶ 45¶ <0.0001 Males 50 19 0.01 22 21 25 0.74 Former smoker 58 30 0.07 Current smoker 19 18 0.77 6MWD m 275+ 390+ 0.03 Metabolic equivalents 2.6 3.7 4.2 <0.0001 NYHA WHO FC I/II 21 35 0.05§ 9 25 26 <0.0001ƒ NYHA WHO FC III/IV 79 65 91 75 74 Anti-nuclear antibodies 38 20 0.06 79 55 32 <0.0001 RAP mmHg 7.3+ 8.1+ ns 11 11 11 0.83 mPAP mmHg 47+ 52+ ns 49 54 54 0.02 CI mL·min−1·m−2 2.3+ 2.5+ ns 2 2 2 0.78 PVR Wood Units ns 11 13 13 0.03 TPVR dyn·s·cm−5 1000+ 1004+ HR (95% CI) 3.8 (2.2–6.6)## <0.001 2.7 (1.9–3.9)## <0.001 2.4 (1.1–5.0)¶¶ 0.025 Data are presented as %, unless otherwise stated. 6MWD: 6-min walking distance; NYHA: New York Heart Association; WHO: World Health Organization; FC: functional class; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; CI: cardiac index; PVR: pulmonary vascular resistance; TPVR: total PVR; HR: hazard ratio; ns: nonsignificant. #: median age at diagnosis; ¶: mean age at study entry; +: approximate value based on data from [42]; §: FC I/II versus III/IV; ƒ: across all groups; ##: univariate analysis; ¶¶: multivariate analysis.
Disclosures
Files in this Data Supplement:
